Mergers & Acquisitions ·
Oculis Holding AG entered into an asset purchase agreement with Accure Therapeutics S.L. to acquire worldwide…
OCSAWOculis Holding AG
Oculis Holding AG entered into an asset purchase agreement with Accure Therapeutics S.L. to acquire worldwide development and commercial rights to Privosegtor (ACT-01) and the early-stage candidate ACT-02. The transaction involves a $3.8 million upfront cash payment and the issuance of up to 2,050,000 Oculis ordinary shares subject to lockup release or milestone vesting. This acquisition terminates Oculis' existing license agreement with Accure, eliminating associated milestone payments and royalties while securing global commercial rights. The closing for Privosegtor is expected by February 28, 2027, contingent on the ACT-01 transaction, with ACT-02 closing expected by March 31, 2027. Oculis Holding AG operates in the biopharmaceutical industry, focusing on neuro-ophthalmology and ophthalmology treatments.